Efficacy and Safety of Tenofovir in the Prevention of Perinatal Transmission of Hepatitis B,a Meta-Analysis |
| |
| Affiliation: | 1. Chongqing Medical University, China;2. Chongqing Three Gorges University, China;1. Unidad de Endoscopia Digestiva, Hospital Universitari i Politècnic La Fe, Grupo de Investigación de Endoscopia Digestiva, IIS La Fe, Valencia, España;2. Centro de Visión por Computador, Departamento de Ciencias de la Computación, Universidad Autónoma de Barcelona, Barcelona, España;3. Unidad de Endoscopia, Servicio de Gastroenterología, Hospital Clínic, IDIBAPS, CIBEREHD, Universidad de Barcelona, Barcelona, España;4. IDIBAPS, CIBEREHD, Barcelona, España;1. Servicio de Aparato Digestivo, Complejo Hospitalario de Navarra, Pamplona, Navarra, España;2. Servicio de Aparato Digestivo, Hospital García Orcoyen, Estella, Navarra, España;1. Department of Internal Medicine, Division of Gastroenterology, Van Education and Research Hospital, Van, Turkey;2. Department of Pediatry, Van Education and Research Hospital, Van, Turkey;3. Department of Psychiatry, BezmialemVakıf University, Istanbul, Turkey;1. Servicio de Aparato Digestivo, Hospital Galdakao-Usansolo, Galdakao, España;2. Biocruces Bizkaia Health Research Institute, Barakaldo, España;3. Laboratorio de Microbiología, Hospital Galdakao-Usansolo, Galdakao, España;4. Unidad de Investigación. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), España;1. Department of Gastroenterology, Affiliated Hospital of Southwest Medical University, Luzhou, China;2. Department of Gastroenterology, Beijing Tsinghua Changgung Hospital Medical Center, Tsinghua University, China;3. Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China;1. Digestive division, Endoscopic center, People''s Hospital of Ningxia Hui Autunomous Region, Yinchuan, China;2. Ningxia Key Laboratory of Cerebrocranial Diseases, Ningxia Medical University, Yinchuan, China;3. 521 Hospital of Norinco Group, Xi’an, China |
| |
| Abstract: | BackgroundTenofovir disoproxil fumarate (TDF) is recommended for the prevention of perinatal transmission of the hepatitis B virus (HBV). This study aimed to systematically assess the efficacy and safety of TDF in pregnant women with chronic HBV and their infants.Material and methodsDatabase searches were performed to identify studies blocking the mother-to-child transmission of the hepatitis B virus with tenofovir. The search included pregnant women with chronic HBV infection administered with TDF compared to the no treatment controls, and data from individual studies were pooled using RevMan v5.3 for meta-analysis.ResultsSeven studies with a total of 911 patients met the inclusion criteria: 433 patients in the TDF group and 478 patients in the non-TDF group. The HBV mother-to-child transmission rate in the tenofovir group was effectively reduced compared to the control group (RR: 0.18, 95% CI: 0.08-0.40). HBV-DNA positivity was also significantly low in infants from TDF group (RR: 0.17, 95% CI: 0.10-0.30) and the TDF treatment resulted in significantly higher anti-HBs production (RR: 1.11, 95% CI: 1.04-1.18). Similarly, maternal HBV-DNA was suppression was significantly high in the TDF group (RR: 34.16, 95% CI: 16.40-71.13). Women treated with TDF and their infants did not result in serious adverse events that are statistically different as compared to the women who did not receive any treatment.ConclusionTreatment of HBV infected pregnant women with TDF can effectively and safely prevent the perinatal transmission of chronic hepatitis B. |
| |
| Keywords: | Tenofovir Hepatitis B virus Mother-to-child transmission Meta-analysis Tenofovir Virus de la hepatitis B Transmisión madre a hijo Metaanálisis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
